Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FERM domain-containing protein 4B (FRMD4B)
- Target
- FRMD4B
- Molecular classification
- Other (Scaffolding protein, signaling complex member), FERM domain-containing protein
01
Overview
FERM domain-containing protein 4B (FRMD4B) is a scaffolding protein containing a FERM protein interaction domain and two coiled-coil domains. It serves as a member of GRP1 signaling complexes, recruited to plasma membrane ruffles during insulin receptor signaling, and plays a role in regulating epithelial cell polarity and cell junction remodeling. FRMD4B influences cardiovascular homeostasis, neural excitability, myelin maintenance, retinal morphogenesis, and is genetically associated with risks in diseases such as ischemic heart failure, celiac disease, Alzheimer’s disease, and autoimmune pancreatitis. Its broad tissue expression and functional significance in diverse biological processes make it a notable candidate for research into therapeutic targeting and as a disease biomarker.
- Other names
- FRMD4BGRSP1GRP1-binding protein GRSP16030440G05RikKIAA1013
02
Mechanism of action
Not directly defined for known drugs; mechanistic insights include modulation of signaling complexes, membrane recruitment following insulin stimulation, and scaffolding for protein-protein interactions relevant to cell polarity.
03
Biological functions
Signal transductionRegulation of epithelial cell polarityCell junction remodelingCardiovascular homeostasisNeural excitability and myelin maintenanceRetinal morphogenesis
04
Disease associations
Cardiovascular disease (ischemic cardiomyopathy, heart failure)Neurodegenerative disease (Alzheimer’s disease)Celiac diseaseAutoimmune pancreatitis (glandular lesions)
05
Safety considerations
No directly cited safety concerns; possible therapeutic challenges likely relate to broad tissue distribution and pleiotropic cellular roles, requiring specificity in targeting to avoid systemic effects
06
Interacting drugs
Specific drugs directly targeting FRMD4B are not cited in available data; however, datasets exist for small molecule perturbations changing FRMD4B expression. Drug perturbation effects from LINCS L1000 and other signature datasets are noted, indicating possible indirect interactions or downstream relevance.
07
Biomarkers
Genetic polymorphisms in FRMD4B for cardiovascular disease risk, celiac disease susceptibility, and glandular lesion risk in autoimmune pancreatitis
Beyond the preview
Go deeper on FERM domain-containing protein 4B (FRMD4B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FERM domain-containing protein 4B (FRMD4B).